US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Vitro Biopharma Appoints Established Life Science Sales Executive to its Board of Directors

Golden, Colorado—February 20, 2013—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, simultaneously accepted the resignation of Mr. Erik Van Horn from its Board of Directors and appointed Pete Shuster, the CEO of Neuromics, Inc. to its Board of Directors.  Mr. Shuster is a seasoned and experienced sales executive.  He is the current owner of Neuromics, Inc., a privately held and profitable business focused on sales of numerous (>2500) specialty life science products including stem cell products manufactured by Vitro Biopharma.  Neuromics, Inc. sales have grown over 5.5-fold since

Vitro Biopharma Launches New Stem Cell Products to Accelerate Bone Growth

May Lead to Faster Recovery of Bone FracturesGolden, Colorado—January 22, 2013—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the launch of a series of products with application to accelerated bone growth, fracture healing and development of new osteoporosis drugs.  The new products are osteoblasts derived from human adult stem cells known as mesenchymal stem cells (MSCs).  These cells lead to bone growth and function to maintain bone density and in the recovery from bone fractures.  Osteoporosis, a disease characterized by reduction in bone density is thought to

Vitro Announces Open Letter to Its Shareholders: 2012 Results Drive Strong Performance in 2013

Golden, Colorado—December 11, 2012—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the following open letter to its shareholders: Dear Fellow Shareholders: I am pleased to report our progress during 2012 including significant advances in our business focused on the development, manufacture and commercial distribution of essential tools to support adult stem cell research and clinical development. The highlights of our achievements in 2012 include: · A new and improved website featuring E-commerce of our products, expanded technical and investor relations

Vitro Biopharma Launches Products for Drug Development & Advancement of Joint Regeneration Technology

Distribution Partner Neuromics to Lead SalesGolden, Colorado—October 9,  2012—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the launch of a series of products for use in the development of advanced treatment of injury and diseases of joints.  The new products are chondrocytes derived from human adult stem cells, mesenchymal stem cells (MSCs).  These cells produce collagen and are critical to proper joint function.  Joint disease and injury often involve defects in collagen production and/or damage to chondrocytes due to inflammation, disease or injury. The new

Vitro Biopharma Signs Agreement with Stemgenesis for Distribution of its Stem Cell Products in China

Golden, Colorado—September 12, 2012—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced an agreement with Stemgenesis, Inc. for the exclusive distribution of its products into the following Chinese Provinces: Shanghai, Beijing, Tianjin, Jiangsu, Shandong, Zhejiang, Anhui, Fujian, Hebei, Liaoning and Heilongjiang. The agreement provides for distribution of the entire Vitro Biopharma product line under specific terms and conditions.  The agreement covers Vitro Biopharma’s adult mesenchymal stem cell (MSC) lines & derivatives, the MSC-Gro™

Vitro Biopharma Advances Commercialization of its Fertility Drugs: Licensing Partner to Seek Registration in International Markets

Golden, Colorado—August 28, 2012—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced advances in the commercialization of its infertility treatment drug, Vitropin™, a highly purified form of FSH produced through Vitro Biopharma’s patented production process. During 2011, Vitro licensed two of its patents and certain rights to other related intellectual property to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies (ART). Dr. Posillico and his team of professionals have recently begun the process of registration of Vitropin™ and related products in

Vitro Biopharma Strengthens and Expands Its Distribution Agreement with Neuromics

Golden, Colorado—July 24, 2012—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced an expanded relationship with a key distributor of its stem cell-based products, privately-held Neuromics, Inc (www.neuromics.com).  Vitro Biopharma officials recently met Neuromics principals at their corporate headquarters in Minneapolis, MN.  Neuromics was formed in 2005 by Pete Shuster, a marketing and sales professional with extensive experience in the computer industry who is now focused on providing integral products to the life science industry.  Neuromics competitive advantage is

Vitro Biopharma Responds to Recent Market Activity

Golden, Colorado—May 1, 2012—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, today responded to recent market activity concerning trading of VODG securities. The Company has become aware that an unaffiliated third party acting independently of the Company and without the prior knowledge of the Company released a promotional report regarding VODG on April 27, 2012 .  While the Company cannot be certain, it is a reasonable inference that this report resulted in significant and unusual trading volume and

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media